应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
CALD 卡利都斯软件
停牌 10-09 19:10:06 EDT
36.00
+0.00
0.00%
最高
36.00
最低
36.00
成交量
0.00
今开
36.00
昨收
36.00
日振幅
0.00%
总市值
23.93亿
流通市值
19.59亿
总股本
6,646万
成交额
0.00
换手率
0.00%
流通股本
5,441万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
全球最高价药物再次易主，天价基因疗法值不值？
21世纪经济报道 · 2022-11-26
全球最高价药物再次易主，天价基因疗法值不值？
全球最贵药物再次刷新！蓝鸟生物基因疗法获FDA批准，价格出炉
药融云 · 2022-09-20
全球最贵药物再次刷新！蓝鸟生物基因疗法获FDA批准，价格出炉
蓝鸟生物公司(BLUE)盘前涨近20% 旗下SKYSONA获FDA加速批准用于治疗早期活性CALD
凤凰网港股 · 2022-09-19
蓝鸟生物公司(BLUE)盘前涨近20% 旗下SKYSONA获FDA加速批准用于治疗早期活性CALD
加载更多
公司概况
公司名称：
卡利都斯软件
所属市场：
NASDAQ
上市日期：
--
主营业务：
Callidus Software Inc.于1996年在美国特拉华州注册成立，他在全球销售绩效管理 (SPM)领域向各种规模的企业提供解决方案，且是此领域的市场和技术领先者。各组织机构在销售规划和绩效尤其是销售和支付渠道、性能和奖惩管理业务中使用SPM系统，以优化其投资。SPM系统还提供持续监控并分析这些业务流程的功能，以了解哪一个是运行良好或这需要修改的程序。销售业绩计划是调整员工与渠道合作伙伴目标及企业目标的关键。
发行价格：
--
{"stockData":{"symbol":"CALD","market":"US","secType":"STK","nameCN":"卡利都斯软件","latestPrice":36,"timestamp":1523995200000,"preClose":36,"halted":3,"volume":0,"delay":0,"floatShares":54410000,"shares":66460419,"eps":-0.310592,"marketStatus":"停牌","change":0,"latestTime":"10-09 19:10:06 EDT","open":36,"high":36,"low":36,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.310592,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1760054400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1069304400000,"exchange":"NASDAQ","adjPreClose":36,"volumeRatio":0},"requestUrl":"/m/hq/s/CALD","defaultTab":"news","newsList":[{"id":"2286132187","title":"全球最高价药物再次易主，天价基因疗法值不值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2286132187","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2286132187?lang=zh_cn&edition=full","pubTime":"2022-11-26 17:33","pubTimestamp":1669455180,"startTime":"0","endTime":"0","summary":"基因疗法可引入功能基因来替代突变基因，以纠正或补偿缺陷和异常基因引起的疾病。 21世纪经济报道记者 魏笑 深圳报道 11月22日，美国FDA宣布澳大利亚制药公司CSL Behring的治疗B型血友病的一次性基因疗法Hemgenix获批，定价为350万美元，刷新了世界上最昂贵治疗方法的记录。 在不到半年的时间里，“全球最贵药物”已三易其主。 值得注意的是，这几款药物均为基因治疗产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/world/gjcj/2022-11-26/doc-imqmmthc6096666.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/gjcj/2022-11-26/doc-imqmmthc6096666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAV","CALD"],"gpt_icon":0},{"id":"2269718295","title":"全球最贵药物再次刷新！蓝鸟生物基因疗法获FDA批准，价格出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2269718295","media":"药融云","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2269718295?lang=zh_cn&edition=full","pubTime":"2022-09-20 14:49","pubTimestamp":1663656598,"startTime":"0","endTime":"0","summary":"据药融云数据显示，蓝鸟生物该基因疗法最早于2021年7月16日首次全球面世，上市国家包括欧盟、挪威、冰岛等国家，获批适应症为肾上腺脑白质营养不良。蓝鸟生物目前拥有约300名员工，比1月底减少了42%。蓝鸟生物预计其现金和短期收入将在2024年上半年为公司带来收益。目前该公司对镰状细胞疾病的基因治疗处于临床研究阶段，没有得到美国FDA的批准，安全性和疗效尚未确定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_3932040000_ea5e2b40001010t8x.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_3932040000_ea5e2b40001010t8x.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["CALD"],"gpt_icon":0},{"id":"2268996322","title":"蓝鸟生物公司(BLUE)盘前涨近20% 旗下SKYSONA获FDA加速批准用于治疗早期活性CALD","url":"https://stock-news.laohu8.com/highlight/detail?id=2268996322","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2268996322?lang=zh_cn&edition=full","pubTime":"2022-09-19 16:27","pubTimestamp":1663576058,"startTime":"0","endTime":"0","summary":"蓝鸟生物公司盘前涨近20%，报7.56美元。蓝鸟生物宣布，美国食品和药物管理局已批准SKYSONA，也被称为elicel，用于减缓4-17岁早期活跃性脑肾上腺脑白质营养不良男孩神经功能障碍的进展。作为SKYSONA加速批准的条件之一，蓝鸟同意向FDA提供确认性的长期临床数据。蓝鸟将美国SKYSONA的批发收购成本定为300万美元。SKYSONA生物制剂许可证申请被美国FDA优先审查，蓝鸟在批准后获得了罕见的儿科优先审查凭证。SKYSONA此前被授予孤儿药、罕见儿科疾病和突破性治疗称号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=e4472459a5bedd3ce65e0d6c75962e4f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","CALD","BK4578","BK4139","BLUE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calliduscloud.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0756},{"period":"6month","weight":0.2606},{"period":"1year","weight":0.1744},{"period":"ytd","weight":0.1485}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Callidus Software Inc.于1996年在美国特拉华州注册成立，他在全球销售绩效管理 (SPM)领域向各种规模的企业提供解决方案，且是此领域的市场和技术领先者。各组织机构在销售规划和绩效尤其是销售和支付渠道、性能和奖惩管理业务中使用SPM系统，以优化其投资。SPM系统还提供持续监控并分析这些业务流程的功能，以了解哪一个是运行良好或这需要修改的程序。销售业绩计划是调整员工与渠道合作伙伴目标及企业目标的关键。","exchange":"NASDAQ","name":"卡利都斯软件","nameEN":"Callidus"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"卡利都斯软件(CALD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供卡利都斯软件(CALD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"卡利都斯软件,CALD,卡利都斯软件股票,卡利都斯软件股票老虎,卡利都斯软件股票老虎国际,卡利都斯软件行情,卡利都斯软件股票行情,卡利都斯软件股价,卡利都斯软件股市,卡利都斯软件股票价格,卡利都斯软件股票交易,卡利都斯软件股票购买,卡利都斯软件股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"卡利都斯软件(CALD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供卡利都斯软件(CALD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}